{
    "Symbol": "RPRX",
    "AssetType": "Common Stock",
    "Name": "Royalty Pharma\u00a0Plc",
    "Description": "Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.",
    "CIK": "1802768",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "110 EAST 59TH STREET, NEW YORK, NY, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-03-31",
    "MarketCapitalization": "17020980000",
    "EBITDA": "1497820000",
    "PERatio": "16.01",
    "PEGRatio": "1.176",
    "BookValue": "14.41",
    "DividendPerShare": "0.81",
    "DividendYield": "0.0295",
    "EPS": "1.78",
    "RevenuePerShareTTM": "4.993",
    "ProfitMargin": "0.357",
    "OperatingMarginTTM": "-0.13",
    "ReturnOnAssetsTTM": "0.0354",
    "ReturnOnEquityTTM": "0.121",
    "RevenueTTM": "2238561000",
    "GrossProfitTTM": "1332971000",
    "DilutedEPSTTM": "1.78",
    "QuarterlyEarningsGrowthYOY": "-0.986",
    "QuarterlyRevenueGrowthYOY": "-0.17",
    "AnalystTargetPrice": "44.83",
    "AnalystRatingStrongBuy": "2",
    "AnalystRatingBuy": "4",
    "AnalystRatingHold": "2",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "16.01",
    "ForwardPE": "8.31",
    "PriceToSalesRatioTTM": "7.16",
    "PriceToBookRatio": "1.931",
    "EVToRevenue": "7.44",
    "EVToEBITDA": "9.28",
    "Beta": "0.46",
    "52WeekHigh": "31.42",
    "52WeekLow": "25.2",
    "50DayMovingAverage": "27.13",
    "200DayMovingAverage": "28.18",
    "SharesOutstanding": "452110000",
    "DividendDate": "2024-09-13",
    "ExDividendDate": "2024-08-16"
}